TY - JOUR
T1 - Invasive pneumococcal disease in the Netherlands
T2 - Syndromes, outcome and potential vaccine benefits
AU - Jansen, Angelique G. S. C.
AU - Rodenburg, Gerwin D.
AU - de Greeff, Sabine C.
AU - Hak, Eelko
AU - Veenhoven, Reinier H.
AU - Spanjaard, Lodewijk
AU - Schouls, Leo M.
AU - Sanders, Elisabeth A. M.
AU - van der Ende, Arie
PY - 2009/4/14
Y1 - 2009/4/14
N2 - With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for similar to 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons >= 90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy. (C) 2009 Elsevier Ltd. All rights reserved.
AB - With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for similar to 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons >= 90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy. (C) 2009 Elsevier Ltd. All rights reserved.
KW - Invasive pneumococcal disease
KW - Epidemiology
KW - Serotype distribution
KW - Disease course
KW - Outcome
KW - 3-YEAR MULTICENTER SURVEILLANCE
KW - CONJUGATE VACCINE
KW - STREPTOCOCCUS-PNEUMONIAE
KW - SEROTYPE DISTRIBUTION
KW - UNITED-STATES
KW - OLDER-ADULTS
KW - CHILDREN
KW - ERA
KW - MENINGITIS
KW - INFECTIONS
U2 - 10.1016/j.vaccine.2009.01.127
DO - 10.1016/j.vaccine.2009.01.127
M3 - Article
VL - 27
SP - 2394
EP - 2401
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 17
ER -